Advertisement
ALT vs DNLI
Which Stock Would AI Choose? Altimmune (ALT) vs. Denali Therapeutics (DNLI) Stock Comparison
Key Takeaways
- ALT (Altimmune) is a late clinical-stage biopharmaceutical company focused on its lead candidate pemvidutide for liver and alcohol-related diseases, while DNLI (Denali Therapeutics) recently transitioned to a commercial-stage company with its first approved therapy, Avlayah.
- Recent market activity reflects two different profiles: ALT has trended lower despite positive clinical data, while DNLI has delivered stronger relative performance driven by a successful drug launch.
- Both companies remain unprofitable, but DNLI now records product revenue and holds a larger cash position, whereas ALT is still pre-revenue and dependent on future clinical milestones.
- Risk profiles diverge sharply: ALT faces binary late-stage clinical and competitive risk, while DNLI carries execution and confirmatory-trial risk tied to an accelerated approval.
- For additional coverage, explore ALT Major News and ALT Today's Price Move, along with DNLI Major News and DNLI Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating biotechnology stocks often weigh clinical-stage innovation against commercial execution. ALT (Altimmune) and DNLI (Denali Therapeutics) offer a useful contrast across that spectrum. Altimmune is developing pemvidutide for serious liver and alcohol-related diseases, with no marketed product yet. Denali has crossed into commercialization with Avlayah, an approved treatment for Hunter syndrome. This stock comparison is relevant to growth-oriented and event-driven traders who follow clinical catalysts, regulatory milestones, and relative performance. Understanding how each company's business model, balance sheet, and recent momentum differ can help investors assess market positioning and risk.
ALT Overview and Recent Performance
ALT (Altimmune) is a late clinical-stage biopharmaceutical company developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a dual glucagon/GLP-1 (glucagon-like peptide-1) receptor agonist in development for MASH (metabolic dysfunction-associated steatohepatitis), AUD (alcohol use disorder), and ALD (alcohol-associated liver disease).
In recent weeks, the company reported positive topline results from its Phase 2 RECLAIM study in AUD, meeting the primary endpoint with a statistically significant reduction in heavy drinking days. It also initiated the global Phase 3 PERFORMA study in MASH. Despite these catalysts, shares have trended lower over recent quarters, reflecting competitive concerns in the crowded GLP-1 space and the long timeline to potential revenue. The company reported cash and investments of approximately $519 million as of mid-2026, with management guiding a runway into 2029.
DNLI Overview and Recent Performance
DNLI (Denali Therapeutics) is a biopharmaceutical company developing therapies for neurodegenerative and lysosomal storage diseases. Its proprietary TransportVehicle platform is designed to deliver biologics across the BBB (blood-brain barrier). The company received accelerated approval from the FDA (U.S. Food and Drug Administration) for Avlayah (tividenofusp alfa) in Hunter syndrome, also known as MPS II (mucopolysaccharidosis type II), marking its first commercial product.
Recent market activity has favored DNLI, which recorded its first product revenue of roughly $3.6 million in its initial full launch quarter and strengthened its balance sheet by selling a Priority Review Voucher for $195 million, lifting pro forma cash above $1.1 billion. The stock has outperformed over the trailing year, though it has pulled back from earlier highs, and its continued approval for Avlayah remains contingent on confirmatory-trial results.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers across varying timeframes, strategies, and risk profiles. Because no single bot suits every market regime, only a curated selection earns a place in the Trending AI Robots section. These featured bots are chosen for their current alignment with market conditions, with individual bots differing in trading style, holding period, performance statistics, and the specific sets of tickers they monitor. For traders seeking data-driven, systematic approaches to relative performance and market positioning, reviewing the Trending AI Robots page can offer a useful starting point for evaluating automated strategies across names like ALT and DNLI.
Head-to-Head Comparison
The two companies differ most fundamentally in stage of development. DNLI has a marketed product and recurring revenue, while ALT remains pre-revenue and reliant on clinical success. Growth drivers also differ: DNLI's near-term catalysts center on Avlayah launch execution and pipeline readouts, whereas ALT's value hinges on late-stage pemvidutide data in MASH, AUD, and ALD.
On risk, ALT faces substantial competitive pressure from larger players in the GLP-1 market and a multi-year path to potential commercialization. DNLI faces commercial execution risk and the obligation to confirm Avlayah's clinical benefit in its COMPASS study. From a financial standpoint, DNLI holds the larger cash balance and a stronger recent relative performance profile, while ALT trades at a lower valuation with a more concentrated pipeline bet.
Tickeron AI Verdict
Based on observable factors including trend consistency, stability, and near-term catalysts, Tickeron's AI would likely lean toward DNLI in the current environment. The combination of an approved product, early commercial traction, a strengthened cash position, and comparatively stronger recent relative performance suggests a more stable, lower-uncertainty profile. ALT, by contrast, carries higher binary risk tied to late-stage trials and a competitive therapeutic landscape. This assessment reflects probabilistic, data-driven analysis rather than a definitive forecast, and positioning can shift as new data and market conditions emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and DNLI is a Hold.
ALT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ALT turned positive on November 02, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALT's RSI Oscillator exited the oversold zone, 37 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 70 cases where ALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +7.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALT as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ALT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (3.498). P/E Ratio (-2.737) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (1678.863) settles around the average of (130.981) among similar stocks. ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
DNLI's RSI Oscillator climbs out of oversold territory
The RSI Indicator for DNLI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 21 of the 26 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DNLI as a result. In 65 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for DNLI just turned positive on October 20, 2026. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
Following a +3.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 206 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 62 cases where DNLI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
DNLI moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for DNLI moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
DNLI broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DNLI entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.841) is normal, around the industry mean (3.498). P/E Ratio (-7.067) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALT | DNLI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 81 | 50 | |
P/E GROWTH RATING 1..100 | 16 | 30 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DNLI's Valuation (82) in the Biotechnology industry is in the same range as ALT (94) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.
DNLI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.
ALT's SMR Rating (96) in the Miscellaneous Commercial Services industry is in the same range as DNLI (98) in the Biotechnology industry. This means that ALT’s stock grew similarly to DNLI’s over the last 12 months.
DNLI's Price Growth Rating (50) in the Biotechnology industry is in the same range as ALT (81) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.
ALT's P/E Growth Rating (16) in the Miscellaneous Commercial Services industry is in the same range as DNLI (30) in the Biotechnology industry. This means that ALT’s stock grew similarly to DNLI’s over the last 12 months.
| ALT | DNLI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 76% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 78% |
| Declines ODDS (%) | 10 days ago 88% | 10 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALT’s FA Score shows that 1 FA rating(s) are green while DNLI’s FA Score has 1 green FA rating(s).
- ALT’s FA Score: 1 green, 4 red.
- DNLI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALT’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).
- ALT’s TA Score: 5 bullish, 3 bearish.
- DNLI’s TA Score: 4 bullish, 6 bearish.
Price Growth
ALT (@Biotechnology) experienced а -4.90% price change this week, while DNLI (@Biotechnology) price change was +2.06% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ALT is expected to report earnings on Nov 12, 2026.
DNLI is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALT has been loosely correlated with OGEN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then OGEN could also see price increases.
| Ticker / NAME | Correlation To ALT | 1D Price Change % | ||
|---|---|---|---|---|
| ALT | 100% | -8.49% | ||
| OGEN - ALT | 54% Loosely correlated | -3.30% | ||
| INDP - ALT | 45% Loosely correlated | -7.35% | ||
| FLNA - ALT | 45% Loosely correlated | -2.03% | ||
| DNLI - ALT | 44% Loosely correlated | -2.36% | ||
| EDIT - ALT | 44% Loosely correlated | -8.91% | ||
More | ||||
DNLI and
Correlation & Price change
A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with VIR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To DNLI | 1D Price Change % | ||
|---|---|---|---|---|
| DNLI | 100% | -2.36% | ||
| VIR - DNLI | 53% Loosely correlated | -3.63% | ||
| SRPT - DNLI | 50% Loosely correlated | -4.76% | ||
| VCYT - DNLI | 50% Loosely correlated | -7.18% | ||
| EDIT - DNLI | 49% Loosely correlated | -8.91% | ||
| DYN - DNLI | 48% Loosely correlated | -3.76% | ||
More | ||||